Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab

CONTEXT: Immune checkpoint blockade is associated with endocrine-related adverse events. Thyroid dysfunction during pembrolizumab therapy, an anti-programmed cell death 1 (PD-1) receptor monoclonal antibody, remains to be fully characterized. OBJECTIVE: To assess the incidence and characteristics of...

Descripción completa

Detalles Bibliográficos
Autores principales: de Filette, Jeroen, Jansen, Yanina, Schreuer, Max, Everaert, Hendrik, Velkeniers, Brigitte, Neyns, Bart, Bravenboer, Bert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095250/
https://www.ncbi.nlm.nih.gov/pubmed/27571185
http://dx.doi.org/10.1210/jc.2016-2300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095250/
https://www.ncbi.nlm.nih.gov/pubmed/27571185
http://dx.doi.org/10.1210/jc.2016-2300

Ejemplares similares